Theriva BiologicsTOVX
13F holders, Q1 2025 (March 31)10holders
3new positions
3sold out
$1.10avg. 13F price*
At the end of Q1 2025, 10 institutions reported holding Theriva Biologics Inc. (TOVX) in their 13F filings, unchanged from Q4 2024. 3 opened new positions and 3 sold out. The largest holders were Ikarian Capital, LLC ($132K), Boothbay Fund Management, LLC ($39K) and Geode Capital Management, LLC ($21K).
- Company
- Theriva Biologics Inc.
- CUSIP
- 87164U508
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $192K |
| Exits | 3 | $16K |
All 13F filers, Q4 2024 → Q1 2025: 174,336 shares bought and 18,126 shares sold, net +156,210 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Ikarian Capital, LLC | 0.04% | New | 120,031 | $132K |
| Boothbay Fund Management, LLC | 0.00% | New | 35,601 | $39K |
| Geode Capital Management, LLC | 0.00% | New | 18,683 | $21K |
| UBS Group AG | 0.00% | Reduce -52.1% | 7,851 | $9K |
| BlackRock, Inc. | 0.00% | No change | 7,568 | $8K |
| Osaic Holdings, Inc. | 0.00% | Reduce -31.7% | 884 | $972 |
| Bank of America Corp. | 0.00% | Add +105.0% | 41 | $45 |
| IFP Advisors, Inc | 0.00% | No change | 11 | $12 |
| SBI Securities Co., Ltd. | 0.00% | No change | 10 | $11 |
| Danske Bank A/S | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is TOVX's weight in each manager's 13F, not the share of Theriva Biologics Inc. the manager owns.